Inspiration Biopharmaceuticals names John Butler as ceo

Replaces Michael Griffith who takes position of cso

Inspiration Biopharmaceuticals, a US biopharmaceutical company focused on the development of treatments haemophilia, has appointed John Butler as ceo. He has replaced Michael Griffith, who has become chief scientific officer and remains company president.

Butler has joined Inspiration from Genzyme, which was acquired by Sanofi in April. While at Genzyme, he was most recently president of the company's rare genetic diseases business. He also led the company's renal, endocrinology, and cardiovascular businesses.

Prior to Genzyme, Butler held sales and marketing positions at Amgen and Hoffmann-La Roche.

You may also like

Manufacturing

CMC Biologics and Inspiration agree supply of IB1001

For the treatment and prevention of bleeding in haemophilia B patients
Pharmaceutical

Optimising process steps and performance with agitated Nutsche filter-dryers

Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Design & Build

Cleanroom Technology launches global cleanroom awards

Introducing the Cleanroom Technology Awards, the global benchmark for cleanroom excellence
Sustainability

ACG Packaging Materials becomes first pharma packaging firm to join WEF Lighthouse Network

The company has joined the World Economic Forum’s Global Lighthouse Network after its Shirwal facility was named a Lighthouse site, making it the world’s first pharmaceutical packaging company to receive the recognition for smart, sustainable manufacturing
Pharmaceutical

testo Saveris 1 update automates environmental monitoring workflows for pharma compliance

New features include automated workflows for efficient environmental monitoring, approvals for secure and compliant changes, and more flexible control of webhooks, as well as further improvements in performance, transparency and usability
Regulatory

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Subscribe now